Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07463183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 35 → 38 locations
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Trial sites expanded: 32 → 35 locations · Eligibility criteria expanded, about 18 words · Secondary endpoints: details revised at 6 of 6 entries Show 3 more changesShow less
    • Trial sites expanded: 32 → 35 locations
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 6 of 6 entries
  3. Study sites: 30 to 32v15
  4. Study sites: 28 to 30v14
  5. Study sites revised (28)v13 See this version in full on ClinicalTrials.gov ↗
  6. Trial sites expanded: 17 → 28 locationsv12
  7. Study sites: 15 to 17v11
  8. Study sites: 13 to 15v10
  9. Study sites: 12 to 13v9
  10. Study sites: 11 to 12v8
  11. Study sites: 9 to 11v7
  12. Study sites: 8 to 9v6
  13. Study sites: 7 to 8v5
  14. Recruitment opened Trial sites expanded: 2 → 7 locations · Start date changed from estimate of Mar 30, 2026 to Mar 24, 2026v4 Show 2 more changesShow less
    • Trial sites expanded: 2 → 7 locations
    • Start date changed from estimate of Mar 30, 2026 to Mar 24, 2026
  15. Study sites: 0 to 2v3
  16. Completion date: Aug 17, 2028 to Dec 21, 2028v2
  17. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Trial Details
NCT Number NCT07463183
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Colitis Ulcerative, Ulcerative Colitis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov